Evidence map›Paper›PMID 41923659›Full record

ArticleAddiction (Abingdon, England)2026

Comparative effectiveness of social-contextual treatments for improving substance-related problems among Black adults: An individual-level data synthesis.

Adriana Espinosa, Angela M Haeny, Lesia M Ruglass, Caravella McCuistian, Ashley Vena, Christopher Roundtree, Joel Lopez, Antonio A Morgan-López, A Kathleen Burlew

Abstract readComparative Study
In one paragraph

Article in Addiction (Abingdon, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Adriana EspinosaDepartment of Psychology, The City College of New York and The Graduate Center, CUNY, New York, New York, USA.ORCID https://orcid.org/0000-0003-1117-8595
Angela M HaenyDepartment of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA.ORCID https://orcid.org/0000-0003-3004-6977
Lesia M RuglassDepartment of Psychology, The City College of New York and The Graduate Center, CUNY, New York, New York, USA.
Caravella McCuistianDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.
Ashley VenaThe Emmes Company: The Emmes Company, LLC, Rockville, Maryland, USA.
Christopher RoundtreeDepartment of Psychiatry and Behavioral Sciences, University of California San Francisco, San Francisco, California, USA.
Joel LopezDepartment of Counseling and Clinical Psychology, Teachers College, Columbia University, New York, New York, USA.
Antonio A Morgan-LópezRTI International: Research Triangle Institute, International, Research Triangle Park, North Carolina, USA.
A Kathleen BurlewDepartment of Psychology, University of Cincinnati, Cincinnati, Ohio, USA.

Funding

The National Drug Abuse Treatment Clinical Trials NetworkUG1DA015831 · NIDA · YALE UNIVERSITY · PI Gail D'Onofrio, Roger D. Weiss · 2015 to 2026
$110.8M
The Ohio Valley Node of the Clinical Trials Network (CTN-0153)UG1DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI T John WINHUSEN · 2015 to 2026
$42.5M
Western States Node of the National Drug Abuse Treatment Clinical Trials Network (TMS for CUD) UG1DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Keith N. Humphreys, Philip Todd Korthuis · 2015 to 2026
$24.6M
Quantifying How Cocaine Users Respond to Fentanyl Contamination in CocaineUG1DA049467 · NIDA · UNIVERSITY OF ILLINOIS AT CHICAGO · PI Niranjan Subhash Karnik, ANTONIO A MORGAN-LOPEZ · 2019 to 2026
$11.2M
Mentoring Emerging Scientists for Careers in Substance Use ResearchR25DA035163 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Carmen L Masson, Gideon St.Helen · 2014 to 2026
$4.6M
Understanding Race-Related Stress as a Mechanism Associated with Alcohol Craving to Inform Culturally-Adapting Alcohol Treatment for Black AdultsK23AA028515 · NIAAA · YALE UNIVERSITY · PI HAENY, ANGELA MARIA · 2021 to 2025
$969k
Development of a Technology-Based HIV Prevention Intervention for Black Women Who Use SubstancesK23DA060073 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Caravella McCuistian · 2024 to 2026
$569k
NIAAA NIH HHS K23 AA028515NIDA NIH HHS K23 DA060073NIDA NIH HHS L30 DA049246NIDA NIH HHS R25 DA035163NIDA NIH HHS UG1 DA013732NIDA NIH HHS UG1 DA015815NIDA NIH HHS UG1 DA015831NIDA NIH HHS UG1 DA049467NIH HHS K23AA028515NIH HHS K23DA060073NIH HHS L30DA049246NIH HHS R25DA035163NIH HHS UG1DA013732NIH HHS UG1DA015815NIH HHS UG1DA015831NIH HHS UG1DA049467
6 · The paper itself

Abstract

BACKGROUND AND

aimsDespite similar substance use levels, Black adults experience greater family, legal, employment and other social-contextual challenges related to recovery than other groups. Substance use treatments that address both substance use and social-contextual factors are uniquely positioned to address these substance-related problems and produce more sustainable improvements in social functioning than treatment as usual (TAU) or behavioral controls (Control). The aim of this study was to evaluate changes in substance-related problems among Black adults, focusing on the comparative effectiveness between social-contextual treatments and TAU/Control.

designIndividual-level data synthesis based on secondary analysis of Black adults enrolled in the National Institute on Drug Abuse (NIDA) Clinical Trials Network (CTN).

settingAll data were collected in the primary studies between 2001 and 2008 at clinics across the United States.

participantsBlack adults who reported cocaine and/or opioid use across nine studies within the NIDA CTN. The sample used herein consisted of individuals from five of these studies who provided data on substance-related problems (n = 532; mean age = 39.34; standard deviation = 9.6). MEASUREMENTS: There were two treatment conditions: Social-contextual (e.g. Motivational Interviewing, Seeking Safety, STAGE 12) and TAU/Control. Moderated nonlinear factor analysis estimated latent scores for substance-related problems, using subscales from the Addiction Severity Index, while accounting for measurement noninvariance across studies, time and covariates. Linear mixed models estimated latent score differences over time between social-contextual treatments and TAU/Control during treatment and from the end of treatment through 12-month follow-up.

findingsBoth treatment groups improved across substance-related problem areas from baseline to the end-of-treatment (Cohen's d = -0.10 to d = -0.47), with effects maintained at 12-month follow-up. Although social-contextual treatments did not statistically significantly outperform TAU/Control from baseline to end-of-treatment, they showed greater effects from end of treatment to 12-month follow-up in family/social [Cohen's d difference (Δd) = -0.47, 95% confidence interval (CI) = -0.57 to -0.38], legal (Δd = -0.20, 95% CI = -0.31 to -0.10) and psychiatric problems (Δd = 0.29, 95% CI = -0.38 to -0.20) than TAU/Control. Sensitivity analyses indicated that Seeking Safety and STAGE 12 predominantly drove post-treatment improvements in family/social problems.

conclusionsSubstance use treatment may yield broader, delayed benefits beyond substance use reduction among Black adults in the United States. Compared with treatment-as-usual, social-contextual treatments can yield more sustainable effects in legal, family and psychiatric areas among Black adults, with interventions such as Seeking Safety and STAGE 12 showing particular benefits in addressing family-related challenges.

Indexed as

Black or African AmericanCocaine-Related DisordersOpioid-Related DisordersSubstance-Related DisordersAdultComparative Effectiveness ResearchFemaleHumansMaleMiddle AgedSecondary Data AnalysisTreatment OutcomeUnited Statesindividual‐level data synthesissocial‐contextual treatmentssocial functioningsubstance‐related problemssubstance usetreatment as usual

Identifiers

PMID41923659
PMCPMC13224082

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.